Abpro Holdings, Inc. has been granted an extension by the Nasdaq Hearings Panel to regain full compliance with Nasdaq listing requirements.
The company's strategic progress includes a reverse stock split, market transfer application, and planned capital strategy.
Abpro is focused on executing its plans, delivering results for shareholders, and advancing its lead candidate ABP-102 in partnership with Celltrion.
Cost Optimization
Achieved ~60% reduction in operating expenses through disciplined streamlining.
Nasdaq Compliance Plan
Completed reverse stock split and plans to increase stockholders' equity for ongoing listing requirements.
Capital Strategy
Has access to up to $44 million in equity financing to support operations and financial milestones through 2026.
Pipeline Momentum
ABP-102, the lead antibody candidate developed with Celltrion, is on track for first-in-human trials in 2026.
Platform Innovation
Advancing DiversImmune® and MultiMab™ platforms for multispecific antibody designs with enhanced selectivity and safety profiles.
- Abpro has made significant progress in cost optimization, compliance planning, and capital strategy.
- The company's lead antibody candidate, ABP-102, is progressing towards important clinical trials in 2026.
- Innovation in antibody designs through platforms like DiversImmune® and MultiMab™ is enhancing value creation for Abpro.
Abpro's extension for Nasdaq listing reflects strategic advancements and commitment to sustainable growth, backed by operational efficiency and innovative pipeline development.